Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition And License Agreements (Details)

v3.4.0.3
Asset Acquisition And License Agreements (Details) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2013
Merck | CERC-301    
Asset Acquisition And License Agreement [Line Items]    
Total Cost of License Agreement   $ 1,500,000
Other Commitment   750,000
Merck | CERC-301 | Research and development expense    
Asset Acquisition And License Agreement [Line Items]    
Initial license acquisition payments   750,000
Merck | COMT Inhibitor    
Asset Acquisition And License Agreement [Line Items]    
Initial license acquisition payments   200,000
Merck | COMT Inhibitor | Maximum | Development Milestone Commitment    
Asset Acquisition And License Agreement [Line Items]    
Potential Additional Milestone Commitment   $ 6,200,000
Lilly | CERC-501    
Asset Acquisition And License Agreement [Line Items]    
Term within execution of license agreement 30 days  
Other Commitment $ 250,000  
Term of the study 9 months  
Lilly | CERC-501 | Research and development expense    
Asset Acquisition And License Agreement [Line Items]    
Initial license acquisition payments $ 750,000